ATA642175A - Verfahren zur herstellung neuer substituierter phenylketone - Google Patents

Verfahren zur herstellung neuer substituierter phenylketone

Info

Publication number
ATA642175A
ATA642175A AT642175A AT642175A ATA642175A AT A642175 A ATA642175 A AT A642175A AT 642175 A AT642175 A AT 642175A AT 642175 A AT642175 A AT 642175A AT A642175 A ATA642175 A AT A642175A
Authority
AT
Austria
Prior art keywords
producing new
new substituted
phenylketone
substituted phenylketone
producing
Prior art date
Application number
AT642175A
Other languages
English (en)
Other versions
AT348985B (de
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to AT706177A priority Critical patent/AT345282B/de
Publication of ATA642175A publication Critical patent/ATA642175A/de
Application granted granted Critical
Publication of AT348985B publication Critical patent/AT348985B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
AT642175A 1974-08-20 1975-08-19 Verfahren zur herstellung neuer substituierter phenylketone AT348985B (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT706177A AT345282B (de) 1974-08-20 1977-10-04 Verfahren zur herstellung neuer diazol bzw. triazol- substituierter phenylketone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB36567/74A GB1517164A (en) 1974-08-20 1974-08-20 Substituted-phenyl ketones and a process for the manufacture thereof
GB2182175 1975-05-21

Publications (2)

Publication Number Publication Date
ATA642175A true ATA642175A (de) 1978-08-15
AT348985B AT348985B (de) 1979-03-12

Family

ID=26255542

Family Applications (1)

Application Number Title Priority Date Filing Date
AT642175A AT348985B (de) 1974-08-20 1975-08-19 Verfahren zur herstellung neuer substituierter phenylketone

Country Status (19)

Country Link
JP (1) JPS6018656B2 (de)
AR (1) AR217041A1 (de)
AT (1) AT348985B (de)
AU (1) AU502104B2 (de)
CA (1) CA1177069A (de)
CH (1) CH620900A5 (de)
DD (1) DD123086A5 (de)
DE (1) DE2537069A1 (de)
DK (1) DK149284C (de)
ES (1) ES440315A1 (de)
FI (1) FI66592C (de)
FR (1) FR2282261A1 (de)
GB (1) GB1517164A (de)
IL (1) IL47936A (de)
LU (1) LU73219A1 (de)
NL (1) NL7509884A (de)
NO (1) NO150199C (de)
PH (1) PH16616A (de)
SE (1) SE426319B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2754112A1 (de) * 1977-12-05 1979-06-13 Kali Chemie Pharma Gmbh 1,4-benzodiazepinderivate, ihre salze und diese verbindungen enthaltende arzneipraeparate
IN184976B (de) * 1996-06-13 2000-10-14 Ranbaxy Lab Ltd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3709898A (en) * 1971-02-09 1973-01-09 Upjohn Co Process for the production of triazolobenzodiazepines and intermediates
JPS526861B2 (de) * 1972-05-27 1977-02-25
ZA735932B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Benzodiazepine derivatives

Also Published As

Publication number Publication date
NL7509884A (nl) 1976-02-24
NO150199C (no) 1984-09-05
ES440315A1 (es) 1977-09-16
SE426319B (sv) 1982-12-27
IL47936A0 (en) 1975-11-25
LU73219A1 (de) 1977-04-15
PH16616A (en) 1983-11-28
AR217041A1 (es) 1980-02-29
CH620900A5 (en) 1980-12-31
FI66592B (fi) 1984-07-31
FR2282261A1 (fr) 1976-03-19
DE2537069A1 (de) 1976-03-04
FR2282261B1 (de) 1978-11-10
CA1177069A (en) 1984-10-30
AU8407475A (en) 1977-02-24
NO752876L (de) 1976-02-23
DK373975A (da) 1976-02-21
DK149284B (da) 1986-04-21
JPS51125048A (en) 1976-11-01
IL47936A (en) 1980-01-31
AT348985B (de) 1979-03-12
AU502104B2 (en) 1979-07-12
NO150199B (no) 1984-05-28
DK149284C (da) 1986-10-13
SE7509268L (sv) 1976-02-23
JPS6018656B2 (ja) 1985-05-11
FI66592C (fi) 1984-11-12
GB1517164A (en) 1978-07-12
DD123086A5 (de) 1976-11-20
FI752350A (de) 1976-02-21
DE2537069C2 (de) 1988-09-08

Similar Documents

Publication Publication Date Title
AT344906B (de) Verfahren zur herstellung neuer cephalosporinverbindungen
DD129644A5 (de) Verfahren zur herstellung neuer prostaglandinvorprodukte
AT342040B (de) Verfahren zur herstellung neuer 2-phenyl-indolderivate
AT337166B (de) Verfahren zur herstellung neuer substituierter benzocycloalkenylalkane
ATA504374A (de) Verfahren zur herstellung neuer haptensteroide
ATA639275A (de) Verfahren zur herstellung neuer rifamycine
ATA343276A (de) Verfahren zur herstellung neuer rifamycin-verbindungen
AT340888B (de) Verfahren zur herstellung neuer quartarer ammoniumverbindungen
DD133949A5 (de) Verfahren zur herstellung neuer benzopyranderivate
AT340901B (de) Verfahren zur herstellung neuer substituierter benzophenone
ATA986075A (de) Verfahren zur herstellung neuer indolderivate
ATA343076A (de) Verfahren zur herstellung neuer rifamycin-verbindungen
ATA924875A (de) Verfahren zur herstellung neuer 5-nitroimida- zolderivate
AT348985B (de) Verfahren zur herstellung neuer substituierter phenylketone
AT351046B (de) Verfahren zur herstellung neuer diharnstoffe
ATA668876A (de) Verfahren zur herstellung neuer basischer ather
AT344898B (de) Verfahren zur herstellung neuer rifamycin-verbindungen
AT348120B (de) Verfahren zur herstellung neuer pseudotri- saccharide
ATA28576A (de) Verfahren zur herstellung neuer 1,3-dichloracetonoxim-o-alkyl-carbonate
AT336200B (de) Verfahren zur herstellung neuer cardenolidacetale
AT353410B (de) Verfahren zur herstellung neuer pseudotrisac- charide
ATA986376A (de) Verfahren zur herstellung neuer haptensteroide
AT346481B (de) Verfahren zur herstellung neuer pseudotrisaccharide
ATA520678A (de) Verfahren zur herstellung neuer 2-anilinooxazolineverfahren zur herstellung neuer 2-anilino-oxazolinverfahren zur herstellung neuer 2-anilino- -oxazoline e
AT350528B (de) Verfahren zur herstellung neuer fluoracylresorcine

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee